secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-07-23T20:07:41+00:00
Accession:  0001599298-26-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q2 2026: Cash $690.7M; HARMONi-6 OS benefit; PDUFA Nov 14
-----------------------------------------------------------------------------

- Cash and investments $690.7M at June 30, 2026; raised $230.8M via ATM in Q2 and $68.4M post-quarter.
- GAAP net loss $215.7M ($0.28/share); Non-GAAP net loss $147.0M ($0.19/share) vs $86.9M ($0.12) in Q2 2025.
- HARMONi updated OS: HR 0.76 in full ITT, consistent in western and Asian patients; BLA PDUFA Nov 14, 2026.
- HARMONi-6 (Akeso) showed OS benefit over tislelizumab (HR 0.66, p=0.0017) in 1L squamous NSCLC.
- Sold ridinilazole to Biossil for $500K upfront + up to $104.5M milestones; clinical collaborations with Arcus, RevMed, GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/0001599298-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/smmt-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer